Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. [electronic resource] by
- Colon-Otero, Gerardo
- Weroha, S John
- Foster, Nathan R
- Haluska, Paul
- Hou, Xiaonan
- Wahner-Hendrickson, Andrea E
- Jatoi, Aminah
- Block, Matthew S
- Dinh, Tri A
- Robertson, Matthew W
- Copland, John A
Producer: 20170712
In:
Gynecologic oncology vol. 146
Availability: No items available.
|
|
8.
|
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. [electronic resource] by
- Wahner Hendrickson, Andrea E
- Haluska, Paul
- Schneider, Paula A
- Loegering, David A
- Peterson, Kevin L
- Attar, Ricardo
- Smith, B Douglas
- Erlichman, Charles
- Gottardis, Marco
- Karp, Judith E
- Carboni, Joan M
- Kaufmann, Scott H
Producer: 20091203
In:
Cancer research vol. 69
Availability: No items available.
|
|
9.
|
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. [electronic resource] by
- Wahner Hendrickson, Andrea E
- Hawthorne, Kieran M
- Goode, Ellen L
- Kalli, Kimberly R
- Goergen, Krista M
- Bakkum-Gamez, Jamie N
- Cliby, William A
- Keeney, Gary L
- Visscher, Daniel W
- Tarabishy, Yaman
- Oberg, Ann L
- Hartmann, Lynn C
- Maurer, Matthew J
Producer: 20150528
In:
Gynecologic oncology vol. 137
Availability: No items available.
|
|
10.
|
BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. [electronic resource] by
- Kanakkanthara, Arun
- Kurmi, Kiran
- Ekstrom, Thomas L
- Hou, Xiaonan
- Purfeerst, Emma R
- Heinzen, Ethan P
- Correia, Cristina
- Huntoon, Catherine J
- O'Brien, Daniel
- Wahner Hendrickson, Andrea E
- Dowdy, Sean C
- Li, Hu
- Oberg, Ann L
- Hitosugi, Taro
- Kaufmann, Scott H
- Weroha, S John
- Karnitz, Larry M
Producer: 20200527
In:
Cancer research vol. 79
Availability: No items available.
|
|
11.
|
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. [electronic resource] by
- Vinayak, Shaveta
- Tolaney, Sara M
- Schwartzberg, Lee
- Mita, Monica
- McCann, Georgia
- Tan, Antoinette R
- Wahner-Hendrickson, Andrea E
- Forero, Andres
- Anders, Carey
- Wulf, Gerburg M
- Dillon, Patrick
- Lynce, Filipa
- Zarwan, Corrine
- Erban, John K
- Zhou, Yinghui
- Buerstatte, Nathan
- Graham, Julie R
- Arora, Sujata
- Dezube, Bruce J
- Telli, Melinda L
Publication details: JAMA oncology Aug 2019
In:
JAMA oncology vol. 5
Availability: No items available.
|
|
12.
|
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. [electronic resource] by
- Moore, Kathleen N
- Secord, Angeles Alvarez
- Geller, Melissa A
- Miller, David Scott
- Cloven, Noelle
- Fleming, Gini F
- Wahner Hendrickson, Andrea E
- Azodi, Masoud
- DiSilvestro, Paul
- Oza, Amit M
- Cristea, Mihaela
- Berek, Jonathan S
- Chan, John K
- Rimel, Bobbie J
- Matei, Daniela E
- Li, Yong
- Sun, Kaiming
- Luptakova, Katarina
- Matulonis, Ursula A
- Monk, Bradley J
Producer: 20200615
In:
The Lancet. Oncology vol. 20
Availability: No items available.
|
|
13.
|
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. [electronic resource] by
- Wahner Hendrickson, Andrea E
- Menefee, Michael E
- Hartmann, Lynn C
- Long, Harry J
- Northfelt, Donald W
- Reid, Joel M
- Boakye-Agyeman, Felix
- Kayode, Olumide
- Flatten, Karen S
- Harrell, Maria I
- Swisher, Elizabeth M
- Poirier, Guy G
- Satele, Daniel
- Allred, Jake
- Lensing, Janet L
- Chen, Alice
- Ji, Jiuping
- Zang, Yiping
- Erlichman, Charles
- Haluska, Paul
- Kaufmann, Scott H
Producer: 20190924
In:
Clinical cancer research : an official journal of the American Association for Cancer Research vol. 24
Availability: No items available.
|
|
14.
|
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. [electronic resource] by
- Hurley, Rachel M
- Wahner Hendrickson, Andrea E
- Visscher, Daniel W
- Ansell, Peter
- Harrell, Maria I
- Wagner, Jill M
- Negron, Vivian
- Goergen, Krista M
- Maurer, Matthew J
- Oberg, Ann L
- Meng, X Wei
- Flatten, Karen S
- De Jonge, Maja J A
- Van Herpen, Carla D
- Gietema, Jourik A
- Koornstra, Rutger H T
- Jager, Agnes
- den Hollander, Martha W
- Dudley, Matthew
- Shepherd, Stacie P
- Swisher, Elizabeth M
- Kaufmann, Scott H
Producer: 20190513
In:
Gynecologic oncology vol. 153
Availability: No items available.
|